Related by context. All words. (Click for frequent words.) 82 confidence interval CI 79 % CI #.#-#.# [006] 77 p = 76 confidence interval #.#-#.# 76 P = .# 76 CI = 76 CI #.#-#.# [002] 74 % CI #.#-#.# [008] 74 p = #.# [002] 73 % CI #.#-#.# [007] 72 p = .# [002] 71 p = #.# [004] 71 CI -#.# 70 % CI #.#-#.# [003] 68 n = 67 nonfatal MI 67 univariate analysis 66 % CI #.#-#.# [001] 66 highest tertile 65 % Confidence Interval 65 CI #.#-#.# [001] 65 AOR = 65 nonsignificant 65 ≥ 64 highest quintile 64 aOR 64 nonobese 64 multivariate adjustment 64 % CI #.#-#.# [004] 63 lowest tertile 63 p = #.# [003] 63 confidence intervals CIs 63 r = 63 placebo p = 63 tertile 63 β = 63 interquartile range 62 sd = 62 p = NS 62 creatinine ratio 62 Hazard Ratio HR 62 multivariable adjusted 62 multivariate analysis 62 -#.# ± [002] 61 CI #.#-#.# p = 61 P ≤ 61 advanced adenoma 61 TT genotype 61 CVD mortality 61 lowest quintile 61 hip BMD 61 CC genotype 60 multivariate adjusted 60 pg ml 60 colorectal adenoma 60 tirofiban 60 mL/min/#.# m 2 60 μmol L 60 tertiles 60 nonfatal stroke 60 recurrent VTE 60 = #.#-#.# 60 parous women 60 biochemical recurrence 60 ng mL 60 nondiabetic patients 60 median PFS 59 nondiabetic 59 kg/m2 59 normotensive 59 placebo p 59 mIU L 59 reinfarction 59 intima media thickness 59 nonfasting triglyceride levels 59 % CI #.#-#.# [005] 59 nonsignificant difference 59 MetS 59 5-FU/LV 59 endometrial thickness 58 #.#/#.# mmHg [001] 58 df = 58 HF hospitalization 58 p = .# [001] 58 postintervention 58 univariate analyzes 58 nonfatal myocardial infarction 58 x ULN 58 multivariate Cox 58 multivariable analysis 58 mmHg diastolic 58 locoregional recurrence 58 recurrent venous thromboembolism 58 HbA1C levels 58 adjunctive placebo 58 BRCA1 mutation carriers 58 femoral neck BMD 58 leukopenia 58 g dL 58 preintervention 58 diastolic BP 58 statistically significant p = 58 lopinavir r arm 58 neurodevelopmental impairment 58 progression TTP 58 euthyroid 58 CR nPR 58 BMI ≥ 58 definite stent thrombosis 58 rs# [003] 58 MADRS score 58 binary restenosis 58 #mg/day [001] 58 nmol liter 58 MACCE 58 ± SD 58 statistically significant p 58 myocardial infarction MI 58 aged ≥ 58 fasting triglyceride levels 57 log# copies mL 57 colorectal adenomas 57 covariates 57 cardiovascular mortality 57 logistic regression analysis 57 p ≤ 57 progesterone receptor negative 57 posttreatment 57 biochemical relapse 57 vertebral fracture 57 nmol L 57 pmol liter 57 #.#-#.# p = 57 rheumatoid factor 57 univariate 57 systolic blood pressures 57 pg mL 57 mmol l 57 MMSE score 57 Secondary endpoints included 57 ipsilateral stroke 57 tibiofemoral 57 tHcy 57 Hazard Ratio = 57 serum concentrations 57 rs# [004] 57 pmol L 57 mmol L 57 achieved ACR# 57 HbA 1c levels 57 colorectal neoplasia 57 oxycodone CR 57 odds ratios ORs 57 logistic regression model 57 ALT elevation 57 nmol 57 ‰ ¥ 57 BMI z 57 ug dose 57 lumbar spine BMD 56 histologically confirmed 56 alanine aminotransferase 56 polyp recurrence 56 Kaplan Meier analysis 56 advanced adenomas 56 hypophosphatemia 56 neutrophil counts 56 FOLFIRI alone 56 leucopenia 56 erythrocyte sedimentation rate 56 TAXUS p value 56 kg m² 56 mg d 56 postop 56 HOMA IR 56 pCR 56 Complication rates 56 mL/min/#.# m2 56 CYP#D# inhibitor 56 ng ml 56 LVEF 56 baseline HbA1c 56 recurrent UTI 56 DAS# [002] 56 advanced neoplasia 56 QTcF 56 â ‰ ¥ 56 methotrexate monotherapy 56 placebo 56 systolic BP 56 plus medroxyprogesterone acetate 56 systolic dysfunction 56 REYATAZ r arm 56 estimated glomerular filtration 56 pT3 56 kcal d 56 diastolic hypertension 56 periprocedural 56 Hazard Ratio 56 hsCRP levels 56 PaO 2 56 μg kg 56 HBeAg negative patients 56 ischemia driven 56 mIU ml 56 comorbidity 56 abacavir lamivudine 56 left ventricular systolic 56 posttransplant 56 atazanavir ritonavir 56 umol L 55 distant metastasis 55 LV dysfunction 55 postoperative AF 55 cytogenetic abnormalities 55 ng dL 55 deep venous thromboses 55 nonvertebral fractures 55 overt hepatic encephalopathy HE 55 hormone receptor negative 55 lispro 55 statistically significant 55 URTI 55 annualized relapse 55 adenoma recurrence 55 mm Hg 55 Baseline characteristics 55 Zometa hazard 55 rs# [002] 55 g dl 55 LV ejection fraction 55 evaluable 55 Multivariate analysis 55 sociodemographic characteristics 55 mL kg 55 clodronate 55 chlorambucil 55 infliximab monotherapy 55 ± 55 preoperative 55 recurrent DVT 55 nulliparous women 55 PSA nadir 55 transferrin saturation 55 serum estradiol 55 preoperative PSA 55 proximal DVT 55 NMIBC 55 XIENCE V demonstrated 55 laboratory abnormalities 55 nmol l 55 fasting insulin 55 severe neutropenia 55 Exclusion criteria 55 endometrial carcinoma 55 refractory ischemia 55 mild renal impairment 55 CCyR 55 nondepressed 55 achieved statistical significance 55 MMSE scores 55 -#.# p = 55 Univariate analysis 55 invasive carcinomas 55 postdischarge 55 mg kg 55 ß = 55 mcg kg 55 multivariate analyzes 55 Secondary endpoints include 55 -#.# mg dL [001] 55 COPD exacerbation 55 chlorthalidone 55 eplerenone 55 #mg QD [001] 55 #mmHg [002] 55 μg mL 55 recurrent ischemia 54 apnea hypopnea index 54 severe exacerbations 54 myocardial infarction stroke 54 elevated LDH 54 systemic embolism 54 psychiatric comorbidities 54 recurrent myocardial infarction 54 Breslow thickness 54 postoperative complication 54 mcg albinterferon alfa 2b 54 prevalences 54 adjunctive ABILIFY 54 CrCl 54 flutamide 54 detrusor overactivity 54 baseline CD4 54 inversely associated 54 IIIa inhibitors 54 leukocyte count 54 mU liter 54 enamel defects 54 prospectively defined 54 comorbidities 54 incidence ≥ 54 mU L 54 nodal metastases 54 mcg QD 54 thromboembolic events 54 HIV uninfected 54 bilateral oophorectomy 54 events MACE 54 receiving ISENTRESS 54 shorter telomere length 54 mcg BID 54 #q# deletion syndrome 54 reach statistical significance 54 arterial thromboembolic events 54 TEAEs 54 tolterodine ER 54 #mg/dL [002] 54 noncarriers 54 hours postdose 54 virologic failure 54 #.#/#.# mm Hg [003] 54 liver histology 54 HbA 1c 54 #OHD 54 CR CRu 54 NNT = 54 carotid IMT 54 creatinine clearance 54 colorectal neoplasms 54 psychiatric morbidity 54 subtrochanteric 54 nonexposed 54 rebleeding 54 -#.# ± [001] 54 HbA1c levels 54 invasive ductal 54 mmHg p = 54 rs# [001] 54 extracapsular extension 54 atypical hyperplasia 54 -#.# log# copies mL 54 composite endpoint 54 log# IU mL 54 seminal vesicle invasion 54 CHD mortality 54 perioperative complications 54 invasive lobular 54 alanine aminotransferase ALT 54 acute cholecystitis 54 β blockers 54 androgen suppression 54 affective psychosis 54 serum IGF 54 IPSS 54 colorectal carcinoma 54 amoxicillin clavulanate 54 β blocker 54 nonobese patients 54 SGPT 54 elevated ALT 54 thyrotropin levels 54 adenoma 54 #OHD levels 54 elevated transaminases 54 nonmetastatic 54 contralateral breast cancer 54 morphometric vertebral fractures 54 lymphocytosis 54 proteinuria 54 pretest probability 54 #mg BID [003] 54 lopinavir r 54 pooled comparator 54 antiretroviral naïve 54 symptomatic VTE 54 stent binary restenosis 54 mg BID 54 IQR 54 febrile neutropenia 54 nasopharyngitis headache 54 dehydroepiandrosterone sulfate 54 FOLFOX4 54 nondrinkers 54 μg L 54 thromboembolism 54 seropositivity 53 CsA 53 nasopharyngitis 53 kappa = 53 ventricular tachyarrhythmia 53 mg p = 53 intact parathyroid hormone 53 Subgroup analyzes 53 endoscopic remission 53 LVSD 53 mg kg dose 53 estrogen receptor negative 53 mg QD 53 EBRT 53 #mmHg [001] 53 oxycodone IR 53 coronary artery calcification 53 SUVmax 53 #.#mmHg 53 severe hypoglycemic 53 histologic subtype 53 mg BID dose 53 #mg BID [001] 53 mild renal insufficiency 53 troponin T 53 renal insufficiency 53 serum creatinine levels 53 statistical significance p 53 protein excretion 53 lymph node metastasis 53 HBeAg positive patients 53 Depressive symptoms 53 osteopenic 53 cerebrovascular accident 53 diastolic blood pressures 53 prostate cancer CaP 53 -#.# mg dL [002] 53 distal colon cancer 53 #.#ng/ml 53 lamivudine monotherapy 53 serum PTH 53 WOMAC pain 53 urine albumin 53 spontaneous bacterial peritonitis 53 unresectable HCC 53 discontinuations due 53 seronegative 53 CIN3 53 Secondary endpoints 53 urinary albumin 53 #.#mmol L [002] 53 echocardiographic parameters 53 latent celiac disease 53 cerebrovascular events 53 plasma adiponectin 53 urolithiasis 53 cerebral infarction 53 mg dL 53 hematologic toxicity 53 aspartate aminotransferase 53 median survivals 53 mmHg 53 quetiapine risperidone 53 homozygotes 53 obstructive CAD 53 Primary endpoints 53 stage IIIb IV 53 aspartate aminotransferase AST 53 min -1 53 Median PFS 53 obstructive coronary artery 53 serum ALT 53 generalized edema 53 HBeAg 53 mg kg Hematide 53 μg liter 53 dietary calcium intake 53 severe hypoglycemia 53 comorbid anxiety 53 cardiovascular hospitalizations 53 urinary excretion 53 nonalcoholic steatohepatitis NASH 53 ABC/3TC 53 experienced virologic failure 53 PSQI 53 SLNB 53 receiving VICTRELIS 53 elevated hsCRP 53 extensive metabolizers 53 PCa 53 ipsilateral 53 placebo Hazard Ratio 53 statistically significant reduction 53 nadroparin 53 Apgar scores 53 comorbid 53 IQR = 53 breast carcinoma 53 mmHg systolic 53 Erythropoietic therapies may 53 -#.# mm Hg 53 AUC0 53 postoperative mortality 53 NPH insulin 53 Viread Emtriva Sustiva 53 familial aggregation 53 coinfected patients 53 VLBW 53 NSTEMI 53 Serum creatinine 53 ejection fractions 53 extrapyramidal symptoms 53 placebo dexamethasone 53 placebo fluoxetine 53 sociodemographic factors 53 serum potassium 53 distal colon 53 conjugated equine estrogen 53 spine BMD 53 mm Hg diastolic 53 T1c 52 gestational hypertension 52 subclinical hyperthyroidism 52 mL min 52 serum PSA 52 adiponectin concentrations 52 statistically significant predictor 52 depressive symptomatology 52 HBeAg seroconversion 52 NNRTI resistance 52 hydroxyvitamin D levels 52 nonpregnant women 52 hypertensives 52 venous thrombosis 52 dapagliflozin plus 52 ECG abnormalities 52 atopy 52 comorbid illnesses 52 EpCAM expression 52 coronary revascularization 52 venlafaxine XR 52 Flu Cy 52 biopsy Gleason 52 serum testosterone 52 de novo AML 52 albumin excretion 52 mg simvastatin 52 μg 52 non valvular atrial 52 #ng/ml 52 eGFR 52 free survival PFS 52 undergoing coronary angiography 52 PRADAXA #mg 52 hepatorenal syndrome 52 -#.# log# 52 HBeAg negative 52 DAS# remission 52 tipranavir r 52 locoregional 52 Multivariate analysis revealed 52 4mg/kg 52 Plasma concentrations 52 FDA defined valvulopathy 52 perimenopausal women 52 malignancy HCM 52 underwent CABG 52 recurrent atrial fibrillation 52 regression coefficient 52 Stent thrombosis 52 prednisone prednisolone plus 52 tumor histology 52 acneform rash 52 lymphadenectomy 52 prepregnancy 52 inhospital 52 GG genotype 52 glycated hemoglobin levels 52 rho = 52 asthma exacerbation 52 microg 52 Median survival 52 r2 = 52 mg ustekinumab 52 microbiologically evaluable 52 proband 52 papillary renal cell carcinoma 52 pyrexia mucositis sepsis febrile 52 mitoxantrone 52 serum urate levels 52 corticosteroid dose 52 lymphovascular invasion 52 multivariable Cox 52 plasma uric acid 52 serum magnesium 52 headache nasopharyngitis 52 SGRQ 52 glycoprotein IIb IIIa inhibitors 52 undergone radical prostatectomy 52 comparator arm 52 methacholine challenge 52 beta blocker therapy 52 diuretic chlorthalidone 52 subclinical hypothyroidism 52 VLBW infants 52 #.#mg/dL 52 ventricular mass 52 familial clustering 52 arterial oxygen saturation 52 noncardiac 52 covariate 52 plasma folate 52 premenopausal 52 HRQoL 52 mEq L 52 Myocardial infarction 52 = -#.# 52 potential confounders 52 HIV RNA 52 octreotide LAR 52 symptomatic intracerebral hemorrhage 52 dalteparin 52 glycated hemoglobin HbA1c 52 hemorrhagic complications 52 symptomatic AF 52 titrated glipizide 52 dysuria 52 thyroid hormone levels 52 ug ml 52 CHD 52 affective psychoses 52 revascularizations 52 PSADT 52 nonobstructive 52 #mg/kg [002] 52 VT VF 52 mg dose 52 postoperative complications 52 elevated IOP 52 LAB GHRH 52 non splenectomized 52 irbesartan 52 hepatic metastases 52 bronchioloalveolar carcinoma 52 PCWP 52 AUCs 52 IM progesterone 52 Folfox 52 lobular cancer 52 Fasting plasma glucose 52 albumin excretion rate 52 chorioamnionitis 52 pretransplant 52 lactate dehydrogenase 52 plus GP IIb 52 GnRH agonist 52 ug kg 52 femoral neck 52 liver decompensation 52 BRCA2 mutation carriers 52 copies ml 52 peripheral edema 52 triacylglycerol concentrations 52 uM 52 unfractionated heparin 52 inhospital mortality 52 adefovir treated 52 statistically nonsignificant 52 FOLFOX 52 adriamycin 52 PANSS scores 52 urate lowering therapy 52 inverse association 52 serum triglycerides 52 mcg dL 52 femoral neck fracture 52 ml kg 52 relapsed MM 52 serum uric acid 52 perioperatively 52 carotid intima media 52 Operative mortality 52 antibody titer 52 coronary stenosis 52 Prognostic significance 52 lumbar spine bone 52 genotypic resistance 52 fractional anisotropy 52 noninferior 52 virological failure 52 nonischemic 52 baseline LDH 52 CTEPH 52 microalbuminuria 52 intravesical therapy 52 ALT normalization 52 Hb A1C 52 repeat revascularization 51 atopic 51 ATACAND 51 mm Hg systolic 51 nonfasting 51 proximal colon 51 coinfected 51 recurrent genital herpes 51 parasitaemia 51 lymphopenia 51 statistically significant differences 51 operable breast cancer 51 N telopeptide 51 desvenlafaxine succinate 51 adenotonsillectomy 51 androgen deprivation 51 mg 51 abdominal irradiation 51 Median progression 51 lifetime abstainers 51 timepoint 51 adenomatous polyps 51 polytherapy 51 distant metastases 51 PROCTOCORT ® Suppository Hydrocortisone 51 macroalbuminuria 51 plasma triglycerides 51 subscales 51 μg ml 51 F FDG PET 51 DAS# scores 51 asthenia 51 radiotherapy RT 51 postoperatively 51 timepoints 51 mRNA expression 51 TURBT 51 coinfection 51 HGPIN 51 ARCOXIA 51 cirrhotic 51 VcMP 51 arthralgia 51 hypoxemia 51 mg TID 51 CRu 51 #.#mmol L [001] 51 thromboembolic 51 RLAI 51 urinary N telopeptide 51 incontinence episodes 51 cilostazol 51 plasma creatinine 51 hypertension diabetes mellitus 51 IFN alfa 51 overt nephropathy 51 μg g 51 p = ns 51 fluorouracil leucovorin 51 pulmonary vascular 51 nonresponders 51 fatigue asthenia 51 neutrophil count 51 quartiles 51 thyroid carcinoma 51 TDF FTC 51 leuprorelin 51 ziprasidone 51 KRAS mutations occur 51 cardiovascular hospitalization 51 serum cortisol 51 IPAH 51 abdominal pain abdominal discomfort 51 response pCR 51 valsartan 51 chromosome #p# [002] 51 #.#/# [005] 51 pamidronate 51 rimonabant #mg 51 Multivariate analyzes 51 serum CRP 51 pulmonary dysfunction 51 LS BMD 51 CHD CVD 51 PLX STROKE targeting 51 collagenous colitis 51 prolactin elevation 51 attain statistical significance 51 RECIST criteria 51 μg dL 51 hypoglycemic events 51 ß blockers 51 postoperative 51 adenomatous 51 virologic response 51 urgent coronary revascularization 51 GSTM1 51 radical prostatectomy RP 51 dyspareunia 51 System IPSS 51 Subgroup analysis 51 XIENCE V vs. 51 thiazide diuretics 51 Charlson comorbidity index 51 nulliparous 51 HAM D# scores 51 dose dexamethasone 51 Acetate Rectal Suppositories 51 imipenem 51 hemoglobin A1c levels 51 CTNNB1 51 intraventricular hemorrhage 51 Thal Dex 51 carotid plaques 51 plus dexamethasone 51 pegylated interferon alfa 2b 51 UGT#A# * 51 underwent surgical resection 51 neutropenia dehydration dyspnea 51 airflow obstruction 51 mg hydrochlorothiazide 51 sleeve lobectomy 51 SCr 51 endometrial hyperplasia 51 plasma lipids 51 HER2 amplification 51 multivariable analyzes 51 severe hypoglycaemia 51 milliliters mL 51 HRCT 51 nonfatal myocardial infarction MI 51 glomerular filtration 51 baseline serum creatinine 51 fasting plasma 51 daunorubicin 51 nicardipine 51 recurrent acute pancreatitis 51 #mg QD [002] 51 graft occlusion 51 EGFR mutation positive 51 EDSS score 51 evaluable patients 51 hyperplastic polyps 51 mcg mL 51 NATRECOR R 51 waist circumferences 51 mycophenolate 51 BRCA2 carriers 51 hyperlipidaemia 51 ATV RTV 51 bronchopulmonary dysplasia 51 CK # plasma concentrations 51 hydroxymethyl coenzyme 51 lignan intake 51 HAQ DI 51 = .# 51 atheroma volume 51 plus MTX 51 copies mL 51 prepregnancy BMI 51 postoperative chemotherapy 51 FluCAM arm 51 μg d 51 preterm neonates 51 undetectable HBV DNA 51 colon rectal 51 kg -1 51 thromboembolic complications 51 symptom severity 51 postprocedure 51 MELD scores 51 nadolol 51 neoplasias 51 cyclophosphamide methotrexate 51 maternal serum 51 DES implantation 51 partial remissions 51 ertapenem 51 anemia hemoglobin 51 preoperative chemotherapy 51 ALT flares 51 confounders 51 myocardial infarction 51 undergone splenectomy 51 hypogonadal 51 Adjuvant chemotherapy 51 schizophreniform disorder 51 albuminuria 51 pT2 51 CDAI 51 moderate renal impairment 51 underwent resection 51 MBq 51 postmenopausal osteoporotic women 51 preeclamptic 51 serum albumin 51 noninferiority 51 EC naproxen 51 thrombocytopenic 51 systolic function 51 metoprolol tartrate 51 dietary folate intake 51 symptomatic intracranial 51 response CCyR 51 hypokalemia 50 glimepiride 50 normoxic 50 asthenia fatigue 50 AST ALT 50 #ug [001] 50 mechanically ventilated patients 50 hyperhomocysteinemia 50 multiple logistic regression 50 retrospective cohort 50 Brief Psychiatric 50 Kaplan Meier survival 50 autonomic dysfunction 50 #.#/#.# mm Hg [001] 50 axillary node 50 #.#g/day 50 urinary albumin excretion 50 neurodevelopmental outcomes 50 Postoperatively 50 ovarian carcinoma 50 comorbid conditions 50 insulin detemir 50 HER2 expression 50 Partial Response 50 seroconversion 50 CaP 50 coronary calcification 50 normal birthweight 50 Logistic regression 50 dyspnea 50 index BMI 50 mg/m2 dose 50 Pneumocystis carinii pneumonia 50 colorectal cancer incidence 50 Montgomery Åsberg Depression 50 fatal myocardial infarction 50 ABCB1 50 8mg/kg 50 PREZISTA ritonavir 50 Kaplan Meier 50 eptifibatide 50 Partial Responses 50 certolizumab 50 concomitant antibiotics 50 nmol L. 50 fractional shortening 50 Multivariate analysis showed 50 hyperlipemia 50 beta carotene supplementation 50 paresthesias 50 anovulatory infertility 50 metastatic GIST 50 endometriosis ovarian cysts 50 contralateral breast 50 noncardiovascular mortality 50 drank pomegranate juice 50 adnexal mass 50 undergoing radical cystectomy 50 detectable HCV RNA 50 TAXUS Express Stent 50 serum GGT 50 log# 50 oxygen saturations 50 cryptogenic 50 contralateral 50 serum homocysteine 50 abciximab 50 serum HBV DNA 50 axillary lymph node 50 intima media thickness IMT 50 apolipoprotein B 50 HCV genotype 50 comorbid depression 50 preoperatively 50 nodal metastasis 50 Pred Forte 50 QRS duration 50 cases/# 50 seroconverted 50 lymph node metastases 50 dose clopidogrel 50 death reinfarction 50 atopic asthma 50 serum lipid levels 50 linaclotide treated 50 TMP SMX 50 IU mL 50 Postoperative 50 ductal breast cancer 50 mcg linaclotide 50 prospectively stratified 50 FOLFIRI 50 alkaline phosphatase 50 peginterferon alfa 2b 50 QALYs 50 FEV ^ sub 50 pulmonary capillary wedge 50 epithelial ovarian cancer 50 corrected QT interval 50 elevated serum creatinine 50 serum parathyroid hormone 50 ALND 50 Asymptomatic 50 EDSS scores 50 plasma cortisol 50 bioavailable testosterone 50 viral titers 50 probands 50 nondiabetics 50 hemodynamically significant 50 PREZISTA r arm 50 secondary efficacy endpoint